Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jasper Therapeutics, Inc. (JSPR : NSDQ)

• Company Description    Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif. Number of Employees: 64

• Price / Volume Information    Yesterday's Closing Price: $6.82 Daily Weekly Monthly 20 Day Moving Average: 369,219 shares Shares Outstanding: 15.02 (millions) Market Capitalization: $102.45 (millions) Beta: 2.69 52 Week High: $26.05 52 Week Low: $3.13 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.67% 8.98% 12 Week 88.40% 65.09% Year To Date -68.10% -69.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2200 BRIDGE PKWY SUITE #102 - REDWOOD CITY,CA 94065 USA ph: 650-549-1400 fax: - ir@jaspertherapeutics.com https://jaspertherapeutics.com

• General Corporate Information    Officers Ronald Martell - President; Chief Executive Officer Thomas G. Wiggans - Chairperson of the Board Herb Cross - Chief Financial Officer Vishal Kapoor - Director Kurt von Emster - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 471871202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 15.02 Most Recent Split Date: 1.00 (0.10:1) Beta: 2.69 Market Capitalization: $102.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.54 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.34 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.43 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -36.89% vs. Previous Quarter: 12.96% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -109.45 12/31/24 - -79.43 ROA 06/30/25 - - 03/31/25 - -89.82 12/31/24 - -68.00 Current Ratio 06/30/25 - - 03/31/25 - 4.31 12/31/24 - 4.98 Quick Ratio 06/30/25 - - 03/31/25 - 4.31 12/31/24 - 4.98 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.81 12/31/24 - 4.11 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©